ADVFN Logo ADVFN

Wir konnten keine Ergebnisse für:
Stelle sicher, dass deine Schreibweise korrekt ist oder versuche deine Suche zu erweitern.

Trends

Toplisten

Es scheint, dass du nicht eingeloggt bist.
Klicke auf den Button unten, um dich einzuloggen und deine zuletzt angesehenen Aktien zu sehen.

Registrieren

Bereits Mitglied? Einloggen

Pepperstone

Jetzt Handeln

Pepperstone
Marktdaten
News
Werkzeuge
Märkte
Entdecken

Hot Features

Follow Feed

Vernetzen Sie sich mit Händlern und Investoren in unserer Follow-Feed-Community.

Optionen-Flow

Erkunden Sie umfassende Optionsdaten und nutzen Sie erweiterte Filter mit Options Flow.

Watchlist

Organisieren und überwachen Sie Ihre Aktien- und Vermögensbeobachtungsliste mit dem Monitor.
Anmelden Premium IconPremium Help Menu
DAX
18.693,37
0,04%
S&P 500
5.304,72
0,70%
Dow Jones
39.069,59
0,01%
Euro vs US Dollar
1,08535
0,38%
Bitcoin
68.806,77
1,30%
Registration Strip Icon for alerts Registrieren Sie sich für Echtzeit-Benachrichtigungen, benutzerdefinierte Portfolios und Marktbewegungen.
Registrieren
  1. Startseite
  2. Investieren
  3. Aktien
  4. USA
  5. NASDAQ
  6. ContraFect Corporation (CFRX)

  7. ContraFect Corporation (CFRX) News

CFRX

ContraFect (CFRX)

ContraFect Corporation
Von:
Sortieren nach:
 Showing the most relevant articles for your search:NASDAQ:CFRX
DatumZeitQuelleÜberschriftSymbolFirma
14/02/202420h24Edgar (US Regulatory)Form SC 13G/A - Statement of acquisition of beneficial ownership by individuals: [Amend]NASDAQ:CFRXContraFect Corporation
15/11/202322h41Edgar (US Regulatory)Form 8-K - Current reportNASDAQ:CFRXContraFect Corporation
08/11/202322h30Edgar (US Regulatory)Form 8-K - Current reportNASDAQ:CFRXContraFect Corporation
03/11/202322h08Edgar (US Regulatory)Form 424B3 - Prospectus [Rule 424(b)(3)]NASDAQ:CFRXContraFect Corporation
03/11/202305h16Edgar (US Regulatory)Form EFFECT - Notice of EffectivenessNASDAQ:CFRXContraFect Corporation
30/10/202322h24Edgar (US Regulatory)Form S-1 - General form for registration of securities under the Securities Act of 1933NASDAQ:CFRXContraFect Corporation
24/10/202322h06Edgar (US Regulatory)Form S-1 - General form for registration of securities under the Securities Act of 1933NASDAQ:CFRXContraFect Corporation
23/10/202322h05Edgar (US Regulatory)Form DEFA14A - Additional definitive proxy soliciting materials and Rule 14(a)(12) materialNASDAQ:CFRXContraFect Corporation
16/10/202313h30GlobeNewswire Inc.ContraFect Announces FDA Clearance of CF-370 IND Application to Proceed With Phase 1 Clinical StudyNASDAQ:CFRXContraFect Corporation
29/09/202317h15Edgar (US Regulatory)Form 8-K - Current reportNASDAQ:CFRXContraFect Corporation
25/09/202314h00Edgar (US Regulatory)Form DEF 14A - Other definitive proxy statementsNASDAQ:CFRXContraFect Corporation
19/09/202314h30GlobeNewswire Inc.ContraFect to Present at the ASM/ESCMID Joint Conference on Drug DevelopmentNASDAQ:CFRXContraFect Corporation
18/09/202313h30GlobeNewswire Inc.ContraFect Announces Submission of IND Application to the FDA for its Development Candidate CF-370NASDAQ:CFRXContraFect Corporation
14/09/202322h05Edgar (US Regulatory)Form PRE 14A - Other preliminary proxy statementsNASDAQ:CFRXContraFect Corporation
28/08/202314h00GlobeNewswire Inc.ContraFect to Present at the World Anti-Microbial Resistance Congress 2023NASDAQ:CFRXContraFect Corporation
18/08/202323h10Edgar (US Regulatory)Form 8-K - Current reportNASDAQ:CFRXContraFect Corporation
14/08/202322h18Edgar (US Regulatory)Form 10-Q - Quarterly report [Sections 13 or 15(d)]NASDAQ:CFRXContraFect Corporation
14/08/202322h10Edgar (US Regulatory)Form 8-K - Current reportNASDAQ:CFRXContraFect Corporation
14/08/202314h30GlobeNewswire Inc.ContraFect Reports Second Quarter 2023 Financial Results and Provides Business UpdateNASDAQ:CFRXContraFect Corporation
25/07/202322h33Edgar (US Regulatory)Form 8-K - Current reportNASDAQ:CFRXContraFect Corporation
27/06/202314h30GlobeNewswire Inc.ContraFect Enters Into a Warrant Exercise Transaction for Proceeds of $9.6 MillionNASDAQ:CFRXContraFect Corporation
27/06/202314h01Edgar (US Regulatory)Current Report Filing (8-k)NASDAQ:CFRXContraFect Corporation
20/06/202314h59GlobeNewswire Inc.ContraFect Data Presentations at ASM Microbe 2023 Demonstrate the Power of the Company’s Proprietary Platform to Discover New Agents Targeting Antibiotic-Resistant Gram-negative PathogensNASDAQ:CFRXContraFect Corporation
08/06/202322h01GlobeNewswire Inc.ContraFect to Present New Data Demonstrating the Potential Efficacy of Its Engineered Lysins Against Antibiotic-Resistant Pathogens at ASM Microbe 2023NASDAQ:CFRXContraFect Corporation
16/05/202312h03Edgar (US Regulatory)Current Report Filing (8-k)NASDAQ:CFRXContraFect Corporation
15/05/202322h28Edgar (US Regulatory)Quarterly Report (10-q)NASDAQ:CFRXContraFect Corporation
15/05/202314h00GlobeNewswire Inc.ContraFect Reports First Quarter 2023 Financial Results and Provides Business UpdateNASDAQ:CFRXContraFect Corporation
04/05/202312h05Edgar (US Regulatory)Notice of Effectiveness (effect)NASDAQ:CFRXContraFect Corporation
28/04/202322h21Edgar (US Regulatory)Securities Registration Statement (simplified Form) (s-3/a)NASDAQ:CFRXContraFect Corporation
26/04/202315h00GlobeNewswire Inc.ContraFect Announces First Patient Dosed in the Phase 1b/2 Study of Exebacase in Patients with Chronic Prosthetic Joint Infections of the KneeNASDAQ:CFRXContraFect Corporation
 Showing the most relevant articles for your search:NASDAQ:CFRX

Kürzlich von Ihnen besucht

EU
JPEU
WisdomTree Short JPY Lon...
BIT
P1TS41
NLBNPIT1TS41 20240620 36...
ASX
G6M
Group 6 Metals Lld
BIT
P1VIC6
NLBNPIT1VIC6 20991231 65...
BIT
P207U4
NLBNPIT207U4 20991231 85...
BIT
P1WVY1
NLBNPIT1WVY1 20240621 21
ASX
OSHCD
EU
SGEID
Euronext G Eni SPA 01062...
COIN
MILLEUR
COIN
DEHUBUST
DeHub
BIT
P1ZZV1
NLBNPIT1ZZV1 20240621 110
NASDAQ
WDJTX
Wells Fargo Dynamic Targ...
BIT
P1UKS0
NLBNPIT1UKS0 20991231 63...
EU
AFLAP
Agence France Locale 0.5...
LSE
94UI
Barclays 25
BIT
P1X0W8
NLBNPIT1X0W8 20991231 76...
Delayed Upgrade Clock
ADVFN Logo
InvestorsHub

Deutschland
Unternehmen
Geschäft
Popular
App herunterladen
App Store
Google Play

Support: +44 (0) 203 8794 460 | support@advfn.de

Durch das Benutzen des ADVFN Angebotes akzeptieren Sie folgende Allgemeine Geschäftsbedingungen

© 2024 ADVFN PLC - Alle Rechte vorbehalten